此应用程序的某些内容目前无法使用。
如果这种情况持续存在,请联系我们反馈与联系
1. (WO2019064231) HIGH MOLECULAR WEIGHT CHITOSAN, PROCESS FOR OBTAINING AND USES THEREOF
注:相关文本通过自动光符识别流程生成。凡涉及法律问题,请以 PDF 版本为准

CLAIMS

1. Method for obtaining a high molecular weight chitosan consisting the following steps:

- providing milled squid pen with a particle size between 63 and 125 μιη;

- reacting NaOH with the particles selected in the previous step, for at least 1.5 hrs at 75 °C, under stirring and in a N2 atmosphere;

for obtaining a high molecular weight chitosan

- optionally comprising a previous washing of the squid pen to eliminate gross impurities.

2. Method for obtaining a high molecular weight chitosan according to the previous claim wherein the step of providing milled squid pen comprises milling squid pen and selecting the milled squid pen with a particle size between 63 and 125 μιη.

3. Method for obtaining a high molecular weight chitosan according to the previous claim wherein the amount of the selected particles is between 4 - 20 g, preferably 5 -10 g.

Λ. Method for obtaining a high molecular weight chitosan according to any one of the previous claims wherein the amount of NaOH is 200 m L.

5. Method for obtaining a high molecular weight chitosan according to any one of the previous claims wherein the NaOH is a solution of 50% (v/v) NaOH.

6. Method for obtaining a high molecular weight chitosan according to any one of the previous claims wherein the reaction time is between 1.5 and 3.5 hrs, preferably 2 hrs.

7. Method for obtaining a high molecular weight chitosan according to any one of the previous claims wherein the obtained chitosan is frozen at -80 °C and/or freeze-dried for 3 days.

8. Method for obtaining a high molecular weight chitosan according to any one of the previous claims further comprising a previous washing of the squid pen to eliminate gross impurities.

9. A chitosa n comprising a molecular weight of 500 - 1200 kDa and an acetylation degree between 5-40%.

10. The chitosan according to the previous claim comprising an acetylation degree up to 30%.

11. The chitosan according to the previous claim comprising an acetylation degree up to 25%, preferably 20%.

12. The chitosan according to the previous claim comprising an acetylation degree up to 15%, preferably 10%.

13. The chitosan according to any of the claims 9-14 wherein the protein concentration is up to 0.1 mg/ml; preferably 0.08-0.025 mg/ml.

1Λ. The chitosan according to the previous claim wherein the chitosan comprises a molecular weight of at least 600 kDa, preferably 700 kDa, more preferably 900 kDa.

15. The chitosan according to the previous claim wherein the chitosan comprises a molecular weight of at least 1000 kDa, preferably 1200 kDa.

16. The chitosan according to the previous claim wherein the chitosan comprises a molecular weight between 500 and 1200 kDa, more preferably between 800 and 1100 kDa.

17. The chitosan according to any of the claims 9-19 wherein the chitosan is β- chitosan.

18. The chitosan according to any of the claims 9-18 or obtainable by the method described in ant of the claim 1-9 for use in medicine or veterinary.

19. The chitosan according to any of the claims 9-18 or obtainable by the method described in ant of the claim 1-9 for use in human or veterinarian regenerative medicine and/or tissue engineering.

20. The chitosan according to any of the claims 9-18 or obtainable by the method described in ant of the claim 1-9 for use according in the treatment or prevention of bone, cartilage, osteochondral, joint, muscle, musculoskeletal, ligament, tendon, connective, ocular, skin, vascular, lymphatic, liver, kidney, spleen, pancreas, reproductive organs, peripheral nerve, spinal cord or brain diseases.

21. The chitosan according to any of the claims 9-18 or obtainable by the method described in any of the claims 1-9, for use the treatment or prevention of human or veterinarian wound healing.

22. The chitosan according to any of the claims 9-18 or obtainable by the method described in any of the claims 1-9, for use as a drug delivery system or as a viscosupplement.

23. A pharmaceutical composition comprising the chitosan described in any the claims 9-22 or obtainable by the method described in any of the claim 1-8, and an active ingredient.

2Λ. A pharmaceutical composition comprising the chitosan described in the previous claim in a therapeutically effective amount or as a pharmaceutically acceptable excipient.

25. The composition according to any of the claims 23-24 further comprising 0.1 to 50 % of said chitosan, preferably 0.5 to 30% (w/v) of chitosan; preferably 0.5 to 10% (w/v) of chitosan.

26. The composition according to any of the claims 23-25 further comprising a second polysaccharide(s), in particular seaweed polysaccharides beta glucan, galactomannan, mucilage, cellulose, inulin, pullulan, dextrin, starch, glycosaminoglycans, or mixtures thereof.

27. The composition according to any of the claims 23-26 further comprising a protein, a growth factor, a digestive enzyme, a metabolic enzyme hormone, a drug, or mixtures thereof, in particular albumin.

28. The com position according to any of the claims 23-27 wherein the protein is selected from the following list: collagen, laminin, albumin, keratin, silk fibroin, fibronectin, or mixtures thereof.

29. The composition according to any of the claims 23-28 further comprising a cell culture media or a buffered media, in particular a liquid, semi-solid, solid or gas cell culture media or a natural, synthetic or semi-synthetic cell culture media.

30. The composition according to any of the claims 23-29 is administered by topical, enteral or parenteral administration.

31. The composition according to any of the claims 23-30 further comprising a plurality of hydrogels.

32. A scaffold, a bead, a microsystema or a nanosystem, comprising the chitosan described in any of the claims 9-22 or obtainable by the method described in any of the claims 1-8 or the pharmaceutical composition described in claims

33. A hydrogel comprising at least 0.1 % of the chitosan the chitosan described in any of the claims 9-22 or obtainable by the method described in any of the claims 1-8.

3Λ. A membrane comprising the chitosan described in any of the claims 9-22 or obtainable by the method described in any of the claims 1-8 or the pharmaceutical composition described in claims 23-31.